ClinicalTrials.gg
CompletedNCT02540954Updated Jun 11, 2021Results posted

Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

A Phase 3 interventional study of Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) in Macular Degeneration, sponsored by Bayer. Completed at 71 sites in 14 countries. Open to participants aged 51 Years and older. Per ClinicalTrials.gov, last updated 2021-06-11.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
336
Allocation
Randomized
Ages
51 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 66 studies testing aflibercept in Macular Degeneration — 2 open to participants now, 5 under way, 2 of them phase 3. aflibercept · Macular Degeneration.

Enrollment
11th of 66
336 · median 55
Started
2015
with 5 others
Phase 3
18 of 66
1 open now
Registered
36th of 66
by date
Lead sponsor
8 of 66
Bayer

Among the 66 studies testing aflibercept in Macular Degeneration, this one is the 11th largest by enrollment, is one of 6 that started in 2015, is one of 18 in phase 3, and was the 36th registered.

Macular Degeneration

1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

2 of the 66 studies testing aflibercept in Macular Degeneration are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About aflibercept

aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 165 Macular Degeneration studies recruiting now, 116 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 51 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 66 studies testing aflibercept in Macular Degeneration, or all of them as a file.
02

Study summary

To compare the efficacy of 2 mg aflibercept administered by two different intravitreal (IVT) treatment regimens to subjects with neovascular age-related macular degeneration (nAMD)

Read the detailed description

330 Patients who have completed at least one year of treatment with aflibercept will be randomized to two different aflibercept regimens and followed for 76 weeks.

03

Conditions studied

  • Macular Degeneration

Keywords

  • Age-related macular degeneration (AMD)
  • Eylea treatment
  • Treat and Extend
  • Intravitreal
04

Who can participate

Ages eligible
51 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The following criteria must have been met at the initial start of aflibercept treatment (i.e. start of aflibercept treatment at least 1 year before this study):

    • Subject had primary subfoveal choroidal neovascularization (CNV) lesions secondary to nAMD, including juxtafoveal lesions that affect the fovea, as evidenced by fluorescein angiography/photography (FA/FP) of the study eye within 3 weeks before the initiation of aflibercept treatment.
    • The area of CNV occupied at least 50% of the total lesion within 3 weeks before the initiation of aflibercept treatment.
    • Documented best-corrected visual acuity (BCVA) was 20/40 to 20/320 (letter score of 73 to 25) in the study eye at the initiation of treatment.
  • Men and women >= 51 years of age
  • The subject's history of aflibercept treatment meets ALL of the following:

    • Treatment in the study eye was initiated with three monthly (-1 week/+2 weeks) doses of 2 mg aflibercept and improvements of visual and anatomic outcomes were observed
    • Following the above initiation phase, the intervals between treatments were between 6 weeks and 12 weeks

Exclusion criteria

Exclusion Criteria:

  • Any prior or concomitant therapy with an or approved agent to treat neovascular AMD in the study eye other than aflibercept.
  • Total lesion size > 12 disc areas (30.5 mm2, including blood, scars and neovascularization) as assessed by fluorescein angiography (FA) in the study eye
  • Subretinal hemorrhage that was:

    1. 50% or more of the total lesion area, or
    2. if the blood was under the fovea, and
    3. the blood under the fovea was 1 or more disc areas in size in the study eye.
  • Scar or fibrosis making up more than 50% of the total lesion in the study eye.
  • Scar, fibrosis, or atrophy involving the center of the fovea in the study eye.
  • Presence of retinal pigment epithelial tears or rips involving the macula in the study eye.
  • Causes of CNV other than AMD in the study eye.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
336 participants (actual)

Study arms

  • Experimental
    Aflibercept extended dosing

    Aflibercept was administered 2mg per injection intravitreal (IVT) in the study eye in Aflibercept extended dosing. Flexible dosing interval is ≥ 8 weeks (no upper limit) based on visual and anatomic outcomes as judged by the investigator. When/if visual and anatomical outcomes indicated that the disease had re-activated, the treatment interval reverted to the last treatment interval in which the disease was inactive (ie, no signs of exudation were observed).

    Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

  • Active comparator
    Aflibercept 2Q8 (2 mg aflibercept administered every 8 weeks)

    Aflibercept was administered 2mg per injection IVT in the study eye in Aflibercept 2Q8. Fixed dosing interval is 8 weeks (±3 days), modification of the treatment interval was not allowed.

    Drug: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Best-corrected Visual Acuity (BCVA) Letter Score for the Study Eye

    Visual function was assessed with the procedure from the ETDRS adapted for the Age Related Eye Disease Study using charts with 70 letters at a starting distance of 4 meters. Charts are organized in 14 lines of decreasing size with 5 letters each. Participants reading up to 19 letters at 4 meters were tested at 1 meter to read the first 6 lines. The score equals the sum of letters read at 1 meter and 4 meters. If more than 19 letters are read at 4 meters the score equals the number of letters read plus 30. The score range is 0 to 100, and a higher score represents better visual function.

    Time frame: From baseline to Week 52

Secondary outcomes

  1. Percentage of Participants Maintaining Vision in the Study Eye

    A participant was classified as maintaining vision if the participant had lost fewer than 15 letters in the ETDRS letter score compared to baseline.

    Time frame: At week 52

  2. Percentage of Participants Who Gained From Baseline 5 or More Letters in the Study Eye

    Time frame: At week 52

  3. Mean Change From Baseline in Central Retinal Thickness (CRT) in the Study Eye

    Retinal characteristic was evaluated using Optical coherence tomography (OCT).

    Time frame: From baseline to week 52

  4. Mean Change From Baseline in Choroidal Neovascularization (CNV) Area in the Study Eye

    Choroidal neovascularization measured by optical coherence tomography (OCT).

    Time frame: From baseline to week 52

  5. Percentage of Participants Who Lost From Baseline 30 or More Letters in the Study Eye

    Time frame: At week 52

  6. Mean Change From Baseline in Total Score for National Eye Institute 25-Item Visual Function (NEI VFQ-25) Questionnaire

    National Eye Institute 25-Item Visual Function Questionnaire (NEI VFQ-25) total score ranges from 0 to 100, where 100 represents the best possible score and 0 represents the worst.

    Time frame: From baseline to week 52

  7. Number of Participants With Treatment-emergent Adverse Events (TEAE)

    Time frame: Started after the first application of aflibercept in the study and less than or equal to 30 days after the last dose of study drug over approximately 1.5 years

07

Results

Posted Apr 8, 2021

Participant flow

Study was conducted at 76 centers in 14 countries or regions, between 29-SEP-2015 (first participant first visit) and 04-JUN-2020 (last participant last visit)

Participant flow — Overall Study
MilestoneAflibercept Extended DosingAflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks)
Started168168
Treated167168
Post-baseline bcva assessment165167
Completed149154
Not completed1914
Withdrew: Physician decision31
Withdrew: Withdrawal by subject65
Withdrew: Lost to follow-up11
Withdrew: Adverse event42
Withdrew: Death03
Withdrew: Treatment failure10
Withdrew: Other reason42

Outcome measures

PrimaryMean Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Best-corrected Visual Acuity (BCVA) Letter Score for the Study Eye

Visual function was assessed with the procedure from the ETDRS adapted for the Age Related Eye Disease Study using charts with 70 letters at a starting distance of 4 meters. Charts are organized in 14 lines of decreasing size with 5 letters each. Participants reading up to 19 letters at 4 meters were tested at 1 meter to read the first 6 lines. The score equals the sum of letters read at 1 meter and 4 meters. If more than 19 letters are read at 4 meters the score equals the number of letters read plus 30. The score range is 0 to 100, and a higher score represents better visual function.

Time frame:
From baseline to Week 52
Reported as:
Mean · Letters read correctly
Mean Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Best-corrected Visual Acuity (BCVA) Letter Score for the Study Eye
Letters read correctlyAflibercept Extended DosingAflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks)
Mean Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Best-corrected Visual Acuity (BCVA) Letter Score for the Study Eye-0.3 ± 7.5-0.5 ± 8.4
Statistical analysis
  • Aflibercept Extended Dosing vs Aflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks) · ANCOVA · p = < 0.0001 · Least squares mean difference: 0.22 · 95% CI -1.51 to 1.96
SecondaryPercentage of Participants Maintaining Vision in the Study Eye

A participant was classified as maintaining vision if the participant had lost fewer than 15 letters in the ETDRS letter score compared to baseline.

Time frame:
At week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Maintaining Vision in the Study Eye
Percentage of participantsAflibercept Extended DosingAflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks)
Percentage of Participants Maintaining Vision in the Study Eye95.294.0
Statistical analysis
  • Aflibercept Extended Dosing vs Aflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks) · Treatment difference in %: 1.1 · 95% CI -3.7 to 6.0
SecondaryPercentage of Participants Who Gained From Baseline 5 or More Letters in the Study Eye
Time frame:
At week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Who Gained From Baseline 5 or More Letters in the Study Eye
Percentage of participantsAflibercept Extended DosingAflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks)
Percentage of Participants Who Gained From Baseline 5 or More Letters in the Study Eye24.221.0
SecondaryMean Change From Baseline in Central Retinal Thickness (CRT) in the Study Eye

Retinal characteristic was evaluated using Optical coherence tomography (OCT).

Time frame:
From baseline to week 52
Reported as:
Mean · μm
Mean Change From Baseline in Central Retinal Thickness (CRT) in the Study Eye
μmAflibercept Extended DosingAflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks)
Mean Change From Baseline in Central Retinal Thickness (CRT) in the Study Eye-24.4 ± 55.2-33.4 ± 47.1
SecondaryMean Change From Baseline in Choroidal Neovascularization (CNV) Area in the Study Eye

Choroidal neovascularization measured by optical coherence tomography (OCT).

Time frame:
From baseline to week 52
Reported as:
Mean · mm*2
Mean Change From Baseline in Choroidal Neovascularization (CNV) Area in the Study Eye
mm*2Aflibercept Extended DosingAflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks)
Mean Change From Baseline in Choroidal Neovascularization (CNV) Area in the Study Eye0.274 ± 2.7230.204 ± 2.813
SecondaryPercentage of Participants Who Lost From Baseline 30 or More Letters in the Study Eye
Time frame:
At week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Who Lost From Baseline 30 or More Letters in the Study Eye
Percentage of participantsAflibercept Extended DosingAflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks)
Percentage of Participants Who Lost From Baseline 30 or More Letters in the Study Eye00.6
SecondaryMean Change From Baseline in Total Score for National Eye Institute 25-Item Visual Function (NEI VFQ-25) Questionnaire

National Eye Institute 25-Item Visual Function Questionnaire (NEI VFQ-25) total score ranges from 0 to 100, where 100 represents the best possible score and 0 represents the worst.

Time frame:
From baseline to week 52
Reported as:
Mean · Score on a scale
Mean Change From Baseline in Total Score for National Eye Institute 25-Item Visual Function (NEI VFQ-25) Questionnaire
Score on a scaleAflibercept Extended DosingAflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks)
Mean Change From Baseline in Total Score for National Eye Institute 25-Item Visual Function (NEI VFQ-25) Questionnaire0.186 ± 9.601-1.694 ± 10.328
Statistical analysis
  • Aflibercept Extended Dosing vs Aflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks) · Mean difference (final values): -1.880 · 95% CI -4.152 to 0.392
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAE)
Time frame:
Started after the first application of aflibercept in the study and less than or equal to 30 days after the last dose of study drug over approximately 1.5 years
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAE)
ParticipantsAflibercept Extended DosingAflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks)
Any TEAE130124
Any serious TEAE2623

Adverse events

Collected over From after the first application of aflibercept in the study to 30 days after the last dose of study drug over approximately 1.5 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aflibercept Extended Dosing0/167 (0%)26/167 (15.6%)60/167 (35.9%)
Aflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks)3/168 (1.8%)23/168 (13.7%)70/168 (41.7%)
Most frequent serious events
Showing 10 of 58
Most frequent serious events
EventAflibercept Extended DosingAflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks)
Myocardial infarctionCardiac disorders3/1670/168
FallInjury, poisoning and procedural complications3/1670/168
Atrial fibrillationCardiac disorders2/1671/168
Retinal haemorrhageEye disorders2/1670/168
PneumoniaInfections and infestations2/1670/168
Humerus fractureInjury, poisoning and procedural complications2/1671/168
OsteoarthritisMusculoskeletal and connective tissue disorders1/1672/168
Transient ischaemic attackNervous system disorders0/1672/168
Acute myocardial infarctionCardiac disorders1/1670/168
BradycardiaCardiac disorders1/1670/168
Most frequent other events
Most frequent other events
EventAflibercept Extended DosingAflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks)
CataractEye disorders17/16719/168
Visual acuity reducedEye disorders14/1674/168
Subretinal fluidEye disorders14/16714/168
NasopharyngitisInfections and infestations4/16712/168
Intraocular pressure increasedInvestigations7/16711/168
Neovascular age-related macular degenerationEye disorders8/16710/168
Choroidal neovascularisationEye disorders9/1679/168
InfluenzaInfections and infestations9/1679/168

Baseline characteristics

Safety analysis set (SAF): included all participants who received any study drug

Age, Continuous
Age, Continuous(years)Aflibercept Extended DosingAflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks)Total
Mean76.3 ± 8.374.7 ± 7.075.5 ± 7.7
Sex: Female, Male
Sex: Female, Male(Participants)Aflibercept Extended DosingAflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks)Total
Female107108215
Male6060120
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Aflibercept Extended DosingAflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks)Total
Hispanic or Latino000
Not Hispanic or Latino136128264
Unknown or Not Reported314071
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Aflibercept Extended DosingAflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks)Total
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White139132271
More than one race000
Unknown or Not Reported283664
Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual
Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual(Letters read correctly)Aflibercept Extended DosingAflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks)Total
Mean69.0 ± 12.170.1 ± 10.969.6 ± 11.5
Central retinal thickness (CRT) in the study eye
Central retinal thickness (CRT) in the study eye(μm)Aflibercept Extended DosingAflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks)Total
Mean257.3 ± 67.8264.4 ± 59.7260.9 ± 63.8
Choroidal neovascularization (CNV) area in the study eye
Choroidal neovascularization (CNV) area in the study eye(mm*2)Aflibercept Extended DosingAflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks)Total
Mean4.695 ± 4.0435.060 ± 4.1054.875 ± 4.070
Total score for National Eye Institute 25-Item Visual Function
Total score for National Eye Institute 25-Item Visual Function(Score on a scale)Aflibercept Extended DosingAflibercept 2Q8 (2 mg Aflibercept Administered Every 8 Weeks)Total
Mean72.889 ± 18.41475.757 ± 15.49574.340 ± 17.034
08

Study locations

71 sites
  • Wien, 1090, Austria
  • Wien, 1140, Austria
  • Toronto, Ontario M4N 3M5, Canada
  • Clinique medicale de l'oeil de l'Estrie
    Sherbrooke, Quebec J1J 2B8, Canada
  • Hradec Kralove, 500 05, Czechia
  • Plzen, 304 60, Czechia
  • Praha 10, 100 34, Czechia
  • Praha 2, 12808, Czechia
  • Praha 5, 150 00, Czechia
  • Paris, Cedex 12 75557, France
  • Bordeaux, 33000, France
  • Dijon Cedex, BP 1542-21, France
  • Lyon Cedex 04, 69317, France
  • Nice Cedex, 06006, France
  • Paris, 75010, France
  • Würzburg, Bayern 97080, Germany
  • Darmstadt, Hessen 64297, Germany
  • Frankfurt, Hessen 60596, Germany
  • Marburg, Hessen 35037, Germany
  • Göttingen, Niedersachsen 37075, Germany
  • Düsseldorf, Nordrhein-Westfalen 40225, Germany
  • Leipzig, Sachsen 04103, Germany
  • Berlin, 10713, Germany
  • Berlin, 12203, Germany
  • Hamburg, 20251, Germany
  • Budapest, 1085, Hungary
  • Debrecen, 4032, Hungary
  • Pecs, 7621, Hungary
  • Roma, Lazio 00133, Italy
  • Roma, Lazio 00198, Italy
  • Genova, Liguria 16132, Italy
  • Brescia, Lombardia 25015, Italy
  • Milano, Lombardia 20122, Italy
  • Milano, Lombardia 20132, Italy
  • Milano, Lombardia 20157, Italy
  • Torino, Piemonte 10122, Italy
  • Catania, Sicilia 95123, Italy
  • Pisa, Toscana 56124, Italy
  • Verona, Veneto 37134, Italy
  • Parma, 43126, Italy
  • Kaunas, LT-50009, Lithuania
  • Vilnius, LT-08661, Lithuania
  • Gdansk, 80-809, Poland
  • Olsztyn, 10-424, Poland
  • Coimbra, 3000-548, Portugal
  • Leiria, 2410-197, Portugal
  • Lisboa, 1649-035, Portugal
  • Porto, 4200-319, Portugal
  • Bratislava, 826 06, Slovakia
  • Bratislava, 851 07, Slovakia
  • Nitra, 949 01, Slovakia
  • L'Hospitalet de Llobregat, Barcelona 08907, Spain
  • Barcelona, 08036, Spain
  • Valencia, 46014, Spain
  • Bern, Switzerland
  • Genève, 1204, Switzerland
  • Southampton, Hampshire SO16 6YD, United Kingdom
  • Liverpool, Merseyside L7 8XP, United Kingdom
  • Great Yarmouth, Norfolk NR31 6LA, United Kingdom
  • Middlesborough, North Yorkshire TS4 3BW, United Kingdom
  • Pontyclun, Rhondda, Cynon, Taff CF72 8XR, United Kingdom
  • Guildford, Surrey GU2 7XX, United Kingdom
  • Newcastle Upon Tyne, Tyne And Wear NE1 4LP, United Kingdom
  • Sunderland, Tyne And Wear SR2 9HP, United Kingdom
  • Rugby, Warwickshire CV22 5PX, United Kingdom
  • Wakefield, West Yorkshire WF1 4DG, United Kingdom
  • Hull, York HU3 2JZ, United Kingdom
  • Colchester, CO3 3NB, United Kingdom
  • London, NW1 5QH, United Kingdom
  • London, SE5 9RS, United Kingdom
  • Manchester, M13 9WL, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.clinicalstudydatarequest.com to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the Study sponsors section of the portal.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2015 to primary completion in Dec 2019, 50 months.

Results were first posted in Apr 2021, 1 year 3 months after primary completion.

Of 77 industry-sponsored phase 3 interventional studies under Macular Degeneration, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 33. This study's 50 months is above that.

Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 20 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2015
First posted
Sep 4, 2015
StartActual
Sep 29, 2015
Primary completionActual
Dec 24, 2019
CompletionActual
Jun 4, 2020
Results first posted
Apr 8, 2021
Last update
Jun 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02540954
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Sep 4, 2015
Start date
Sep 29, 2015
Primary completion
Dec 24, 2019
Completion
Jun 4, 2020
Results posted
Apr 8, 2021
Last update
Jun 11, 2021

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion